Nichole Tucker

In an interview with Targeted Oncology, Marcia S. Brose, MD, PhD, discussed a multiple trial analysis of patients treated with larotrectinib over a median of 24 months.

Pembrolizumab is now FDA approved in combination with chemotherapy and with or without bevacizumab, for the treatment of patients with persistent, recurrent or metastatic cervical cancer whose tumors express PD-L1.

The combination of abemaciclib and endocrine therapy has been approved by the FDA as an adjuvant treatment for a subgroup of patients with hormone receptor-positive, HER2-negative, node-positive, early breast cancer.

A novel ATR inhibitor displayed early signals of activity and was tolerable in patients with solid tumor harboring various molecular alterations.

In an interview with Targeted Oncology, Nino Balanchivadze, MD, FACP, discussed the toxicity profile of platinum pemetrexed with pembrolizumab in patients with nonsquamous NSCLC treated in the KEYNOTE-189 study and how demographics and clinical characteristics may impact treatment.

All clinical trials of allogeneic CAR T cells developed by Allogene Therapeutics, Inc have been halted by the FDA pending an investigation of a chromosomal abnormality event.

Alpha DaRT, an intraumoral conformal alpha-irradiation strategy, has been granted a second breakthrough device designation by the FDA.

Zanidatamab in combination with evorpacept has been dosed for the first time in a patient with HER2-low breast cancer.

A subgroup analysis of the phase 3 COSMIC-311 study revealed no key differences in the survival and responses observed with cabozantinib based on the age of patients with RAI-refractory differentiated thyroid cancer.

In an interview with Targeted Oncology™, Michael Chuong, MD explained of the validity of the MRI-guided radiation technique for use in patients with pancreatic cancer, how it compares with CT-guided radiation, and how a shift toward MRI-guided radiation may impact patients with pancreatic cancer in the future.

The ASSURE trial is actively recruiting patients with chronic lymphocytic leukemia to receive acalabrutinib in an investigation of its safety and efficacy.

A phase 2 study suggests that tipifarnib may be more beneficial for patients with CMML, MDS, or MPNs and RAS pathway mutations than the general population of patients with these disease.

Based on results from the DESTINY-Breast03 clinical trial, trastuzumab deruxtecan has been granted another breakthrough therapy designation by the FDA.

Treatment with the investigational agent SY-2101 has begun in a phase 3 clinical trial of patients with newly-diagnosed acute promyelocytic leukemia.

In an interview with Targeted Oncology, Brad S. Kahl, MD, provided an efficacy update from the LOTUS-2 study and discussed multiple agents showing promise for the treatment of relapsed/refractory diffuse large B-cell lymphoma.

Positive findings from the phase 3 VISION have led the FDA to grant priority review to 177Lu-PSMA-617 for patients with metastatic castration-resistant prostate cancer.

The FDA has accepted and granted priority review to the supplemental biologics license application for the PD-1 inhibitor cemiplimab-wlc for the treatment of patients with recurrent or metastatic cervical cancer whose disease progressed on or after chemotherapy.

In the MagnetisMM-1 study, elranatamab induces response with tolerable safety in patients with relapsed or refractory multiple myeloma.

Following its success in acute myeloid leukemia and other cancers, devimistat is being explored as a treatment option for clear cell sarcoma in a phase 1/2 trial.

According to early clinical trial results, taletrectinib can induce responses in patients with ROS1-positive non–small cell lung cancer.

The FDA has accepted a supplemental biologic application for nivolumab plus ipilimumab and chemotherapy as a potential treatment option for unresectable advanced, recurrent or metastatic esophageal squamous cell carcinoma.

In an interview with Targeted Oncology during the SOHO Annual Meeting, Elisabetta Abruzzese, MD, provided key recommendations for managing pregnancy and chronic myeloid leukemia.

Mehdi Hamadani, MD and Bertram Glass, MD recently debated on the role of allogeneic hematopoietic stem cell transplant for the treatment of aggressive B-cell lymphoma now that chimeric antigen receptor T cells have entered the landscape.

The phase 3 PROpel clinical trial has achieved its primary end point of improvement in radiographic progression-free survival in men with metastatic castration resistant prostate cancer using the novel combination of olaparib and abiraterone.

In an interview with Targeted Oncology, Michael Wang, MD, discussed the evolution of treatment in the MCL space specifically with the emergence of chimeric antigen receptor T cells.

Compared with historic controls, the use of adjuvant VAL-083 after chemoradiotherapy and temozolomide may improve outcomes for select patients with glioblastoma multiforme.

In patients with KRAS-mutant non–small cell lung cancer, treatment with rigosertib in combination with nivolumab showed promising signals of efficacy and safety.

The FDA has granted fast track designation to the HER2-targeted chimeric antigen receptor-macrophage, CT-0508, for the treatment of patients with solid tumors.

In an interview with Targeted Oncology™ during the SOHO Annual Meeting, Carole Miller, MD, discussed results from the REVEAL study and how the findings can be used to aid future research.

The FDA has granted approval to mobocertinib for the treatment of adult patients with locally advanced or metastatic EGFR exon 20 insertion–mutant metastatic non–small cell lung cancer, as detected by an FDA-approved test, and who have received prior platinum-based chemotherapy.